$ALKS
Alkermes plc. Stock $alks

$alks Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-Q Financial Statement

#000110465914032259 Filed on April 30, 2014

Income Statement

Concept	2014 Q1	2013 Q1
Revenue	$130.2M	$163.4M
YoY Change	-20.32%	25.23%
Cost Of Revenue	$38.84M	$47.99M
YoY Change	-19.07%	-6.08%
Gross Profit	$91.37M	$115.4M
YoY Change	-20.84%	45.38%
Gross Profit Margin	70.17%	70.63%
Selling, General & Admin	$42.55M	$34.68M
YoY Change	22.7%	-10.62%
% of Gross Profit	46.57%	30.04%
Research & Development	$52.14M	$35.80M
YoY Change	45.64%	-20.8%
% of Gross Profit	57.06%	31.01%
Depreciation & Amortization	$22.55M	$18.32M
YoY Change	23.1%	-11.06%
% of Gross Profit	24.68%	15.87%
Operating Expenses	$94.69M	$70.48M
YoY Change	34.35%	-26.28%
Operating Profit	-$15.89M	$18.98M
YoY Change	-183.72%	-217.19%
Interest Expense	$3.356M	$11.47M
YoY Change	-70.75%	-217.07%
% of Operating Profit		60.44%
Other Income/Expense, Net	-$4.695M	-$11.12M
YoY Change	-57.77%	3606.0%
Pretax Income	-$20.59M	$7.866M
YoY Change	-361.73%	-111.6%
Income Tax	$3.766M	$4.867M
% Of Pretax Income		61.87%
Net Earnings	-$24.40M	$3.000M
YoY Change	-913.33%	-104.73%
Net Earnings / Revenue	-18.74%	1.84%
Basic Earnings Per Share	-$0.17	$0.02
Diluted Earnings Per Share	-$0.17	$0.02
COMMON SHARES
Basic Shares Outstanding	143.4M shares	133.3M shares
Diluted Shares Outstanding	143.4M shares	139.7M shares

Balance Sheet

Concept	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$552.3M	$221.4M
YoY Change	149.5%	16.23%
Cash & Equivalents	$156.3M	$96.96M
Short-Term Investments	$395.9M	$124.4M
Other Short-Term Assets	$45.90M	$19.10M
YoY Change	140.31%	51.59%
Inventory	$55.40M	$43.48M
Prepaid Expenses
Receivables	$123.2M	$124.6M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$776.8M	$408.6M
YoY Change	90.11%	20.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$269.0M	$288.4M
YoY Change	-6.74%	-4.81%
Goodwill	$92.74M	$92.74M
YoY Change	0.0%	0.0%
Intangibles	$525.0M	$576.0M
YoY Change	-8.85%	-6.77%
Long-Term Investments	$149.5M	$82.80M
YoY Change	80.56%	48.65%
Other Assets	$22.50M	$21.71M
YoY Change	3.63%	-18.98%
Total Long-Term Assets	$1.059B	$1.062B
YoY Change	-0.28%	-3.13%
TOTAL ASSETS
Total Short-Term Assets	$776.8M	$408.6M
Total Long-Term Assets	$1.059B	$1.062B
Total Assets	$1.835B	$1.470B
YoY Change	24.84%	2.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$24.30M	$18.28M
YoY Change	32.9%	-0.64%
Accrued Expenses	$59.50M	$58.60M
YoY Change	1.54%	-3.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.750M	$6.750M
YoY Change	0.0%	117.74%
Total Short-Term Liabilities	$92.76M	$85.93M
YoY Change	7.95%	-3.63%
LONG-TERM LIABILITIES
Long-Term Debt	$356.0M	$362.3M
YoY Change	-1.74%	-17.92%
Other Long-Term Liabilities	$10.23M	$23.26M
YoY Change	-56.02%	165.8%
Total Long-Term Liabilities	$366.2M	$385.5M
YoY Change	-5.01%	-14.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$92.76M	$85.93M
Total Long-Term Liabilities	$366.2M	$385.5M
Total Liabilities	$496.0M	$517.9M
YoY Change	-4.24%	-10.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$506.6M	-$499.9M
YoY Change	1.34%	-4.76%
Common Stock	$1.856B	$1.460B
YoY Change	27.11%	5.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$17.96M	$5.380M
YoY Change	233.81%	842.21%
Treasury Stock Shares	692.7K shares	313.5K shares
Shareholders Equity	$1.340B	$952.4M
YoY Change
Total Liabilities & Shareholders Equity	$1.835B	$1.470B
YoY Change	24.84%	2.44%

Cashflow Statement

Concept	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$24.40M	$3.000M
YoY Change	-913.33%	-104.73%
Depreciation, Depletion And Amortization	$22.55M	$18.32M
YoY Change	23.1%	-11.06%
Cash From Operating Activities	-$3.500M	$55.40M
YoY Change	-106.32%	262.09%
INVESTING ACTIVITIES
Capital Expenditures	$5.685M	$8.259M
YoY Change	-31.17%	-200.72%
Acquisitions
YoY Change
Other Investing Activities	-$267.0M	-$103.5M
YoY Change	157.97%	666.67%
Cash From Investing Activities	-$272.7M	-$111.8M
YoY Change	143.92%	417.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$250.0M
YoY Change
Debt Paid & Issued, Net	$1.688M	$1.688M
YoY Change	0.0%
Cash From Financing Activities	264.9M	17.60M
YoY Change	1405.11%	291.11%
NET CHANGE
Cash From Operating Activities	-3.500M	55.40M
Cash From Investing Activities	-272.7M	-111.8M
Cash From Financing Activities	264.9M	17.60M
Net Change In Cash	-11.30M	-38.80M
YoY Change	-70.88%	2055.56%
FREE CASH FLOW
Cash From Operating Activities	-$3.500M	$55.40M
Capital Expenditures	$5.685M	$8.259M
Free Cash Flow	-$9.185M	$47.14M
YoY Change	-119.48%	100.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	84500000	USD
CY2013Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	38749000	USD
CY2014Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	11964000	USD
CY2013Q4	alks	Marketable Securities At Amortized Cost MarketableSecuritiesAtAmortizedCost	261266000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	21405000	USD
CY2013Q4	alks	Marketable Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses MarketableSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses	160000	USD
CY2013Q4	alks	Marketable Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses MarketableSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses	78000	USD
CY2013Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	282433000	USD
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	Alkermes plc.
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001520262
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	395948000	USD
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	alks	Minimum Number Of Commercial Drug Products In Portfolio MinimumNumberOfCommercialDrugProductsInPortfolio	20	product
CY2014Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	144515176	shares
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Use of Estimates</font></i></p> <p style="MARGIN: 0in 0in 0pt 0.25in;"> </p> <p style="TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates and judgments and methodologies, including those related to revenue recognition and related allowances, its collaborative relationships, clinical trial expenses, the valuation of inventory, impairment and amortization of intangibles and long-lived assets, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments and derivative instruments, litigation and restructuring charges. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.</font></p> </div>
CY2014Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	item
CY2014Q1	alks	Marketable Securities At Amortized Cost MarketableSecuritiesAtAmortizedCost	528255000	USD
CY2014Q1	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount	1547000	USD
CY2014Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	17630000	USD
CY2014Q1	alks	Marketable Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses MarketableSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses	399000	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	45941000	USD
CY2014Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	123154000	USD
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	524989000	USD
CY2014Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	149491000	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	22495000	USD
CY2014Q1	us-gaap	Assets Assets	1835478000	USD
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2259000	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	10230000	USD
CY2014Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	25061000	USD
CY2014Q1	alks	Marketable Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses MarketableSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses	47000	USD
CY2014Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	545439000	USD
CY2013Q1	alks	Marketable Securities Realized Gain MarketableSecuritiesRealizedGain	39000	USD
CY2014Q1	alks	Marketable Securities Realized Loss MarketableSecuritiesRealizedLoss	-3000	USD
CY2013Q1	alks	Marketable Securities Realized Loss MarketableSecuritiesRealizedLoss	-5000	USD
CY2014Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	225758000	USD
CY2014Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	291017000	USD
CY2014Q1	us-gaap	Available For Sale Securities Debt Maturities Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost	516775000	USD
CY2014Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	225679000	USD
CY2014Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	290908000	USD
CY2014Q1	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	516587000	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	1448000	USD
CY2014Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	1547000	USD
CY2014Q1	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Fair Value HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue	1547000	USD
CY2014Q1	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	1547000	USD
CY2014Q1	alks	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Number Of Investments Transfer From Level1 To Level2 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisNumberOfInvestmentsTransferFromLevel1ToLevel2	0	item
CY2014Q1	alks	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Number Of Investments Transfers From Level2to Level1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisNumberOfInvestmentsTransfersFromLevel2toLevel1	0	item
CY2013Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	1526000	USD
CY2014Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	1310000	USD
CY2014Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss	-216000	USD
CY2014Q1	alks	Share Price Of Equity Investment SharePriceOfEquityInvestment	34.50
CY2014Q1	us-gaap	Fair Value Assumptions Exercise Price FairValueAssumptionsExercisePrice	5.88
CY2014Q1	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P6Y3M11D
CY2014Q1	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0231	pure
CY2014Q1	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.712	pure
CY2014Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	19251000	USD
CY2013Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	18410000	USD
CY2014Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	21076000	USD
CY2013Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	15581000	USD
CY2014Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	15076000	USD
CY2013Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12227000	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	55403000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	46218000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	428136000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	432598000	USD
CY2014Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	163606000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	153646000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	268992000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	274490000	USD
CY2014Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12576000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	60000000	USD
CY2014Q1	us-gaap	Goodwill Gross GoodwillGross	92740000	USD
CY2014Q1	us-gaap	Goodwill Goodwill	92740000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	640600000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	115611000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	524989000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	65000000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	70000000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	70000000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	70000000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	24297000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	19493000	USD
CY2014Q1	us-gaap	Due To Employees Current DueToEmployeesCurrent	14210000	USD
CY2013Q4	us-gaap	Due To Employees Current DueToEmployeesCurrent	28101000	USD
CY2014Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	36706000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	36283000	USD
CY2014Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	83750000	USD
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	91173000	USD
CY2014Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	3200000	USD
CY2014Q1	us-gaap	Treasury Stock Value TreasuryStockValue	17959000	USD
CY2014Q1	us-gaap	Long Term Debt LongTermDebt	362713000	USD
CY2013Q4	us-gaap	Long Term Debt LongTermDebt	364293000	USD
CY2014Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	6750000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	6750000	USD
CY2014Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	355963000	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	357543000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13420000	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7881000	USD
CY2014Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	600000	USD
CY2013Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	400000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24354000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2999000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	143358000	shares
CY2013Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	133272000	shares
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1854596000	USD
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	8044000	USD
CY2013Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	6405000	shares
CY2014Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	143358000	shares
CY2013Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	139677000	shares
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11105000	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2084000	shares
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3766000	USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4867000	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-506628000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	167562000	USD
CY2013Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	194669000	USD
CY2013Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	134154000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	27535000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	570138000	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	537565000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	92740000	USD
CY2013Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	87764000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14891000	USD
CY2013Q4	us-gaap	Assets Assets	1577588000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2974000	USD
CY2014Q1	alks	Manufacturing And Royalty Revenues ManufacturingAndRoyaltyRevenues	111280000	USD
CY2014Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	3702000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	100897000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	29169000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12580000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	12213000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	512402000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	776771000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	1382000	USD
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	17833000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1553337000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	10574000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-482274000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	1065186000	USD
CY2014Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-11000000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	92759000	USD
CY2014Q1	us-gaap	Liabilities Liabilities	495977000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	1339501000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1577588000	USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	145137639	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	144444951	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	137792626	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	138482571	shares
CY2014Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	692688	shares
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	689945	shares
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18321000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7881000	USD
CY2013Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	4513000	USD
CY2013Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3346000	USD
CY2013Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-533000	USD
CY2013Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7541000	USD
CY2013Q1	alks	Prepayment Of Penalty On Debt Refinancing PrepaymentOfPenaltyOnDebtRefinancing	3733000	USD
CY2013Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	795000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3472000	USD
CY2013Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	4785000	USD
CY2013Q1	alks	Increase Decrease In Inventory Prepaid Expenses And Other Assets IncreaseDecreaseInInventoryPrepaidExpensesAndOtherAssets	-1176000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	26596000	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-878000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1091000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8259000	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	119000	USD
CY2013Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	142437000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-111828000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	16847000	USD
CY2013Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	4513000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	-2074000	USD
CY2013Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1688000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	17593000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-272674000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-38931000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	264909000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-11237000	USD
CY2014Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	787000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	156325000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96961000	USD
CY2013Q1	alks	Manufacturing And Royalty Revenues ManufacturingAndRoyaltyRevenues	146919000	USD
CY2013Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	14626000	USD
CY2013Q1	us-gaap	Contracts Revenue ContractsRevenue	1877000	USD
CY2013Q1	us-gaap	Sales Revenue Net SalesRevenueNet	163422000	USD
CY2013Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	47991000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35800000	USD
CY2013Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34679000	USD
CY2013Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10322000	USD
CY2013Q1	us-gaap	Restructuring Charges RestructuringCharges	12300000	USD
CY2013Q1	us-gaap	Costs And Expenses CostsAndExpenses	144438000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	18984000	USD
CY2013Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	171000	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	11473000	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	184000	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11118000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	7866000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2531000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	143000	USD
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	511000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22553000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26885000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3142000	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4695000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-20588000	USD
CY2014Q1	us-gaap	Costs And Expenses CostsAndExpenses	146105000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15893000	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	130212000	USD
CY2014Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">1. THE COMPANY</font></b></p> <p style="MARGIN: 0in 0in 0pt 0.25in;"> </p> <p style="TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on our own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. We have a diversified portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (“CNS”) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes has a research and development (“R&D”) center in Waltham, Massachusetts; R&D and manufacturing facilities in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia and Wilmington, Ohio.</font></p> </div>
CY2014Q1	us-gaap	Restructuring Reserve Translation Adjustment RestructuringReserveTranslationAdjustment	500000	USD
CY2014Q1	us-gaap	Restructuring Reserve RestructuringReserve	8537000	USD
CY2013Q4	us-gaap	Restructuring Reserve RestructuringReserve	7296000	USD
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5917160	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Share Price SharePrice	42.25
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	250000000	USD
CY2014Q1	alks	Stock Issued Issuance Costs StockIssuedIssuanceCosts	1600000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1835478000	USD
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	55304000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	135892000	USD
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	17079000	USD
CY2014Q1	us-gaap	Contracts Revenue ContractsRevenue	1853000	USD
CY2014Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	38839000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52140000	USD
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	42550000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2014Q1	us-gaap	Interest Expense InterestExpense	3356000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1850000	USD
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	13420000	USD
CY2014Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	7163000	USD
CY2014Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4916000	USD
CY2014Q1	alks	Increase Decrease In Inventory Prepaid Expenses And Other Assets IncreaseDecreaseInInventoryPrepaidExpensesAndOtherAssets	13678000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3084000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-965000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	13000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5685000	USD
CY2014Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	351489000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	11028000	USD
CY2014Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	7163000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1688000	USD
CY2013Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	2450000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	1453000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	248406000	USD

Files In Submission

Name	View Source	Status
0001104659-14-032259-index-headers.html	Edgar Link	pending
0001104659-14-032259-index.html	Edgar Link	pending
0001104659-14-032259.txt	Edgar Link	pending
0001104659-14-032259-xbrl.zip	Edgar Link	pending
a14-8308_110q.htm	Edgar Link	pending
a14-8308_1ex31d1.htm	Edgar Link	pending
a14-8308_1ex31d2.htm	Edgar Link	pending
a14-8308_1ex32d1.htm	Edgar Link	pending
alks-20140331.xml	Edgar Link	completed
alks-20140331.xsd	Edgar Link	pending
alks-20140331_cal.xml	Edgar Link	unprocessable
alks-20140331_def.xml	Edgar Link	unprocessable
alks-20140331_lab.xml	Edgar Link	unprocessable
alks-20140331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALKS
Alkermes plc. Stock $alks

2014 Q1 Form 10-Q Financial Statement

#000110465914032259 Filed on April 30, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALKS Alkermes plc. Stock $alks

2014 Q1 Form 10-Q Financial Statement

#000110465914032259 Filed on April 30, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALKS
Alkermes plc. Stock $alks